Spots Global Cancer Trial Database for Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection

Official Title: A Prospective, Phase II Trial of a Trimodality Regimen for Stage III (N2) Non-small-cell Lung Cancer Using Concurrent Chemoradiotherapy as Induction Treatment Followed by Subsequent Resection

Study ID: NCT01926483

Conditions

Non-small Cell Lung Cancer Stage IIIA

Interventions

Neoadjuvant Chemoradiotherapy

Study Description

Brief Summary: The investigators hypothesized that the Neoadjuvant Chemoradiotherapy was a beneficial treatment for Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer, so we try to evaluate the security of treatment, the QoL of patients and the influence to the PFS and OS.

Detailed Description: Scheme: Patients will receive different chemotherapy regimens depending on the pathological type. Squamous cell carcinoma:Docetaxel/Cisplatin and concurrent radiation (46Gy/23f) followed by surgery, consolidate Docetaxel/Cisplatin 2 cycles. Non-squamous cell carcinoma:Pemetrexed/Cisplatin and concurrent radiation (46Gy/23f) followed by surgery, consolidate Pemetrexed/Cisplatin 2 cycles.